AGM 1470

Drug Profile

AGM 1470

Alternative Names: TNP 470

Latest Information Update: 25 Nov 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer EntreMed; Takeda; TAP Pharmaceutical Products
  • Class
  • Mechanism of Action Aminopeptidase inhibitors; Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Cancer; Cervical cancer; Kaposi's sarcoma; Leukaemia; Lymphoma; Renal cancer

Most Recent Events

  • 25 Nov 2002 Discontinued - Phase-I for Cervical cancer in USA (IV-infusion)
  • 25 Nov 2002 Discontinued - Phase-I for Leukaemia in USA (unspecified route)
  • 25 Nov 2002 Discontinued - Phase-I for Lymphoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top